Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.21
(
0.00%
)
US TECH 100
23,461.40
(
-0.25%
)
Dow Jones
46,309.92
(
0.22%
)
Brent Oil
100.37
(
3.69%
)
Bitcoin
69,640.00
(
-1.78%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 166692

Friday, 03/21/2014 3:28:42 PM

Friday, March 21, 2014 3:28:42 PM

Post# of 257275
GSK/THRX—The CHMP today approved Revinty Ellipta (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/03/news_detail_002044.jsp&mid=WC0b01ac058004d5c1 ), which appears to be the same product (or a minor reformulation) as Relvar Ellipta, which was endorsed by the CHMP in Oct 2013 (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002673/smops/Positive/human_smop_000591.jsp&mid=WC0b01ac058001d127 ). If anyone understands the distinction here, please post.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today